139 related articles for article (PubMed ID: 20726808)
1. Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease.
Błogowski W; Marlicz W; Smereczyński A; Lawniczak M; Lewosiuk A; Starzyńska T
Immunopharmacol Immunotoxicol; 2011 Jun; 33(2):398-402. PubMed ID: 20726808
[TBL] [Abstract][Full Text] [Related]
2. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
Cohen-Ezra O; Avni Y; Morgenstern S; Ben-Ari Z
Harefuah; 2012 Dec; 151(12):675-8, 721. PubMed ID: 23330258
[TBL] [Abstract][Full Text] [Related]
3. [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
López-Martín C; de la Fuente-Fernández E; Corbatón P; Sánchez MC; Gisbert JP
Gastroenterol Hepatol; 2011 Jan; 34(1):16-9. PubMed ID: 21168244
[TBL] [Abstract][Full Text] [Related]
4. [Portal vein hypertension during azathioprine therapy in patients with Crohn's disease--a frequent phenomenon?].
Ehmsen L; Marko C; Breidert M
Dtsch Med Wochenschr; 2008 May; 133(18):950-3. PubMed ID: 18431703
[TBL] [Abstract][Full Text] [Related]
5. [Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease].
Schumann M; Preiss JC; Loddenkemper C; Günther U; Somasundaram R; Siegmund B; Zeitz M
Dtsch Med Wochenschr; 2008 Sep; 133(38):1897-900. PubMed ID: 18788068
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine.
Buster EH; van Vuuren HJ; Zondervan PE; Metselaar HJ; Tilanus HW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):68-72. PubMed ID: 18090994
[TBL] [Abstract][Full Text] [Related]
7. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Musumba CO
Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
[TBL] [Abstract][Full Text] [Related]
8. Nodular regenerative hyperplasia of the liver secondary to azathioprine in a patient with inflammatory bowel disease.
Bryant DL; Miles CJ; Gearry RB
N Z Med J; 2010 Apr; 123(1313):74-6. PubMed ID: 20581898
[TBL] [Abstract][Full Text] [Related]
9. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
Calabrese E; Hanauer SB
J Crohns Colitis; 2011 Feb; 5(1):48-53. PubMed ID: 21272804
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
11. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.
Seiderer J; Zech CJ; Diebold J; Schoenberg SO; Brand S; Tillack C; Göke B; Ochsenkühn T
Eur J Gastroenterol Hepatol; 2006 May; 18(5):553-5. PubMed ID: 16607155
[TBL] [Abstract][Full Text] [Related]
12. [Azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
Ruiz-Clavijo D; Arín A; Vila JJ; Albéniz E; Picazo R; Casi M
An Sist Sanit Navar; 2013 Sep; 36(2):353-6. PubMed ID: 24008542
[TBL] [Abstract][Full Text] [Related]
13. Myelotoxicity and hepatotoxicity during azathioprine therapy.
de Boer NK; Mulder CJ; van Bodegraven AA
Neth J Med; 2005 Dec; 63(11):444-6. PubMed ID: 16397313
[TBL] [Abstract][Full Text] [Related]
14. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
Vernier-Massouille G; Cosnes J; Lemann M; Marteau P; Reinisch W; Laharie D; Cadiot G; Bouhnik Y; De Vos M; Boureille A; Duclos B; Seksik P; Mary JY; Colombel JF
Gut; 2007 Oct; 56(10):1404-9. PubMed ID: 17504943
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine induced serious portal hypertension: a case series of three IBD patients and review of the literature.
Dooremont D; Decaestecker J; De Wulf D; Ghillebert G; Van Vlierberghe H; Van Dorpe J; Baert F
Acta Gastroenterol Belg; 2013 Sep; 76(3):342-6. PubMed ID: 24261031
[TBL] [Abstract][Full Text] [Related]
16. Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.
van Asseldonk DP; Kanis BM; de Boer NK; van Bodegraven AA
Digestion; 2009; 79(4):211-4. PubMed ID: 19390192
[TBL] [Abstract][Full Text] [Related]
17. [Thiopurine-induced hyperammonaemic encephalopathy in a patient with Crohn's disease].
Laish I; Pomeranz I; Kitay-Cohen Y; Konikof F
Harefuah; 2012 Dec; 151(12):692-5, 720. PubMed ID: 23330262
[TBL] [Abstract][Full Text] [Related]
18. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
19. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
20. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury.
Arnott ID; Ghosh S
Eur J Gastroenterol Hepatol; 2000 May; 12(5):569-73. PubMed ID: 10833103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
